Send us a textThis episode dives into the billion-dollar Ozempic class action lawsuit, revealing how confusion over brand-name drugs versus compounded versions raises critical questions about liability, FDA guidelines, and patient safety. We explain the risks tied to GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro, including side effects such as gastroparesis, gallbladder issues, and even sudden blindness. The episode highlights the gray areas of off-label use, physician responsibility, and compounding pharmacy practices, underscoring why this case could reshape perceptions of drug safety and pharmaceutical accountability. Are you eager to explore more about health and wellness? Discover an all natural solution to combating the GLP-1 Receptor Agonist craze. Click on the link below and explore the Feel Great System - a clinically proven approach to boosting natural GLP-1 production, suppressing appetite and improving both your metabolism and weight.https://ufeelgreat.com/usa/en/c/LiveFreeAs a Decoding Health viewer, you get wholesale pricing and a money back guarantee. Give it a try and let us know your results.https://imbiopharma.com/https://www.linkedin.com/in/urban-a-kiernan-ph-d-8568b621/https://www.youtube.com/@DecodingHealthPodcastThank you to our sponsor - iMetabolic Biopharma Corporation: Together, we can be the next stage in developing a revolutionary approach to drug discovery. We give communities the opportunity to invest in their own health as we improve how drugs are discovered to make them more effective and affordable. Visit https://imbiopharma.com/ to learn more.

Ver todos los episodios